The estimated Net Worth of Arch Management Iii Llcthre... is at least $3.32 Milión dollars as of 18 November 2014. Arch Llcthre owns over 250,000 units of Concert Pharmaceuticals Inc stock worth over $243,165 and over the last 10 years Arch sold CNCE stock worth over $3,072,500.
Arch has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Arch sold 250,000 units of CNCE stock worth $3,072,500 on 18 November 2014.
The largest trade Arch's ever made was selling 250,000 units of Concert Pharmaceuticals Inc stock on 18 November 2014 worth over $3,072,500. On average, Arch trades about 250,000 units every 0 days since 2014. As of 18 November 2014 Arch still owns at least 29,052 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Arch Llcthre stock trades at the bottom of the page.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... a Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: